Phase II trial finds zilebesiran lowers systolic blood pressure in patients with uncontrolled hypertension
Among individuals with cardiovascular disease or high cardiovascular risk and uncontrolled hypertension on multiple anti-hypertensive agents, a single subcutaneous dose of zilebesiran 300 mg led to a 5-mmHg reduction in…